v ::INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES::
ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

STUDY TO KNOW THE COMPARISON OF EFFICACY OF DICLOFENAC AND PETHIDINE SUPPOSITORY IN PAIN MANAGEMENT OF RENAL COLIC PATIENTS ADMITTED IN EMERGENCY DEPARTMENT

AUTHORS:

Dr. Abid Nawaz Khan Adil, Dr. Ashraf Ali Jafrani, Dr. Adeel Tariq, Dr. Amjad Mehmood khan

ABSTRACT:

Objective: Renal colic is a major cause of admission in emergency department. Treatment in the ED is limited to pain management because more than 90% of kidney stones are spontaneous. The currently used analgesics are selected according to the experience of doctors and different theories from various sources. The purpose of this analysis was to compare the common drugs used for renal colic (pethidine and diclofenac). Study Design: A single-blind randomized study. Place and Duration: In the Emergency department of Mayo Hospital Lahore for One year duration from October 2017 to October 2018. Methods: In this single-blind randomized study, ninety renal colic patients who were admitted in ED were randomized into each of 3 treatments which include pre-treatment suppositories diclofenac suppository pethidine and (50 mg, iv), diclofenac suppository (50 mg) or in combination. In this sense, treatment response and hospital stay duration were compared. Results: The first line drug to reduce severity of pain was diclofenac below 25 years of age subjects. Diclofenac and Pethidine has good efficacy and pain control in patients aged 25 to 46 years. In contrast, older than 45 years of age, pethidine is recommended. We also observed minimum duration of hospital stay in patients receiving pethidine. Conclusion: It can be concluded that for controlling pain, morphine is much better and decreasing the time of hospital stay with Renal colic patients. Key words: Pain relief, Emergency department, Renal colic.

FULL TEXT

Top
  • Follows us on
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.